Breaks Categories: Stock Spotlights

ThursdayDec 15, 2016 1:25 pm

NetworkNewsBreaks – Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) Resolves Patent Litigation Regarding Schizophrenia Treatment

Vanda Pharmaceuticals (NASDAQ: VNDA) recently resolved its patent litigation against Apotex regarding Apotex's Abbreviated New Drug Application seeking approval of its generic version of Vanda's Fanapt® (iloperidone). Under a licensing agreement, Vanda has granted Apotex a non-exclusive license to manufacture and commercialize its version of Fanapt® in the U.S., effective November 2, 2027. Fanapt® in 2009 was approved by the FDA for the treatment of schizophrenia in adults. In 2012, the drug was approved for marketing in Israel and Argentina. To view the full press release, visit: http://nnw.fm/XSt0U About Vanda Pharmaceuticals Inc. Vanda is a specialty pharmaceutical company focused on…

Continue Reading

ThursdayDec 15, 2016 1:21 pm

NetworkNewsBreaks – Ocera Therapeutics, Inc. (NASDAQ: OCRX) Targets Hepatic Encephalopathy, a Complication of Liver Cirrhosis, with OCR-002

Ocera Therapeutics (NASDAQ: OCRX) is focused on the development of OCR-002 (ornithine phenylacetate) to treat hyperammonemia and subsequent hepatic encephalopathy (HE). An estimated eight million people in the U.S. suffer from chronic liver disease and approximately one million suffer from liver cirrhosis. HE is a debilitating and progressive complication of liver cirrhosis or liver failure marked by mental changes including confusion, impaired motor skills, and disorientation. Severe HE can cause stupor, coma and even death. Currently, there are no drug treatments that can be given intravenously to hospitalized patients with acute HE. To learn more visit www.ocerainc.com About Ocera Ocera…

Continue Reading

ThursdayDec 15, 2016 1:18 pm

NetworkNewsBreaks – CytoDyn Inc. (CYDY) Advances Clinical Trials for PRO 140 for HIV Infection

Cytodyn (OTCQB: CYDY) is focused on enhancing the lives of people with infectious diseases through the development of new antibody treatments to battle human immunodeficiency virus (HIV) infection. An estimated 1.2 million people in the United States were living with HIV at the end of 2013, the most recent year for which this information is available. Cytodyn recently reported the first several patients have been treated in its phase 3 clinical trial with PRO 140, its proprietary drug that can significantly reduce viral burden in people infected with HIV. PRO 140 works by blocking the HIV co-receptor CCR5 on T-cells…

Continue Reading

WednesdayDec 14, 2016 1:58 pm

NetworkNewsBreaks – Vericel (NASDAQ: VCEL) Receives FDA Approval for MACI®; Shares Soar

Shares of Vericel Corp. (NASDAQ: VCEL) are up more than 60% mid-day after the company broke news of the approval of MACI® (autologous cultured chondrocytes on porcine collagen membrane) by the U.S. Food and Drug Administration (FDA) for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. MACI is the first FDA-approved cellularized scaffold product that applies tissue engineering processes to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee. "We believe that the introduction of MACI, along with investments to expand our commercial organization…

Continue Reading

TuesdayDec 13, 2016 2:44 pm

NetworkNewsBreaks – Achaogen, Inc. (AKAO) Proposes Common Stock Public Offering, Proceeds to Advance Plazomicin

Achaogen (NASDAQ: AKAO) has initiated an underwritten public offering of up to 5,750,000 shares of its common stock, all of which are offered by the company. Additionally, Achaogen expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 862,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The company said it intends to use the net proceeds to fund the ongoing development and preparation for potential commercialization of its lead candidate plazomicin, for which the company yesterday announced positive results in phase 3 cUTI and CRE clinical…

Continue Reading

TuesdayDec 13, 2016 2:06 pm

NetworkNewsBreaks – MJP International (MJPI) Takes Aim at “Burgeoning” Texas Market with New Distribution Agreement

Shares of MJP International (OTC: MJPI) are climbing in morning trade after the green products and services company announced its distribution agreement with Texas-based O.C Construction. Per the agreement, O.C Construction will have the exclusive rights to sell and distribute MJP’s products – including different types of wind turbine and solar panels - in parts of Texas. "Over $372 million dollars was invested on solar installations in Texas in 2015. Installed solar capacity in Texas has grown by 65% over the last year. We believe that there is great potential in the Texas market for growth and we will strive…

Continue Reading

TuesdayDec 13, 2016 2:04 pm

NetworkNewsBreaks – Moxian (MOXC) Marketing Solutions Amp-up O2O Commerce

The Online-to-Offline (O2O) market is increasingly desirable to merchants in many industries. Drawing potential customers from online browsing and into a physical store, however, takes strategy. Moxian, Inc. (NASDAQ: MOXC) has created an O2O platform to improve the consumer to merchant connection, enabling businesses to better market and advertise online and potentially attract them to an in-store purchase. “Moxian’s O2O platform targets small- and medium-sized enterprises, including traditional brick-and-mortar vendors, being designed to help them connect with prospects and customers at a deeper level. By integrating social media features, entertainment and gamification, and business intelligence capabilities, the Multi-Channel Social Commerce…

Continue Reading

TuesdayDec 13, 2016 2:01 pm

NetworkNewsBreaks – eXp World Holdings, Inc. (EXPI) Keeps Costs Low, Consumer Interest High

eXp Realty LLC, the agent-owned cloud brokerage of holding company eXp World Holdings (OTCQB: EXPI), is structured to take advantage of consumer preferences toward online browsing while also providing clients the personal service they desire when shopping for a home. “eXp World Holdings combines advanced technology from its cloud-based environment with the value that consumers see from working face-to-face with professionals. Because many future home buyers start their searches online, the company cuts costs by cutting out physical brick and mortar offices, yet maintains a high level of service by navigating the home buying process with clients while giving information…

Continue Reading

MondayDec 12, 2016 1:43 pm

NetworkNewsBreaks – Sysorex (SYRX) Prices $2.0M Registered Direct Offering; Shares Down

Shares of Sysorex (NASDAQ: SYRX) tumbled more than 30% after the developer of analytics software and solutions announced a registered direct offering of shares of its common stock with gross proceeds of approximately $2.0 million. The closing of the offering is expected to take place on or about December 15, 2016. Sysorex says it will use gross proceeds for general corporate purposes. To view the full press release, visit: http://nnw.fm/c3g0F About Sysorex Sysorex develops the systems and solutions that power the data-driven enterprise. With an innovative approach to big data, analytics and the Internet of Things (IoT), we blend virtual…

Continue Reading

FridayDec 09, 2016 11:50 am

NetworkNewsBreaks – Net Element, Inc. (NETE) Payment Solutions are Ideal for Technology-Driven Millennial Demographic

Mobile payments are expected to record a CAGR of 80% to more than $500 billion from now until 2020, pushed partially by an increasingly large number of millennials using their phones to make a payment of some sort. Net Element, Inc. (NASDAQ: NETE) is set to capitalize on this trend by providing a variety of secure payment solutions. “The millennial generation plays a critical role in leading the adoption of consumer technologies. This is one of the key reasons that professionals from a number of industries watch millennials to better recognize social and consumer behavior changes that are to come.…

Continue Reading